<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-371-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROQUIN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HAYAT PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HAYAT PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HAYAT PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p style="margin-left:-45pt; margin-right:-51.5pt; text-align:justify">Ciproquin tablet contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. It works by killing bacteria that cause infections. It only works with specific strains of bacteria.</p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>It is used in adults to treat:</strong></p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Respiratory tract infections</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Long lasting or recurring ear or sinus infections</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Urinary tract infections</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Genital tract infections in men and women</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Gastro-intestinal tract infections and intra-abdominal infections</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Skin and soft tissue infections</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Bone and joint infections</p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->To prevent infections due to the bacterium <em>Neisseria meningitides,</em></p><p style="margin-left:-27.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Anthrax inhalation exposure.</p><p style="margin-left:-40.5pt; margin-right:-51.5pt">It may be used in the management of patients with low white blood cell counts who have a fever that is suspected to be due to a bacterial infection.</p><p style="margin-left:-40.5pt; margin-right:-51.5pt">If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to ciprofloxacin.</p><p style="margin-left:-40.5pt; margin-right:-51.5pt"><strong><u>&nbsp;</u></strong></p><p style="margin-left:-40.5pt; margin-right:-51.5pt"><strong><u>Children and adolescents</u></strong></p><p style="margin-left:-40.5pt; margin-right:-51.5pt">It is used in children and adolescents under specialist medical supervision, to treat:</p><p style="margin-left:-9.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->lung and bronchial infections in children and adolescents suffering from cystic fibrosis</p><p style="margin-left:-9.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->complicated urinary tract infections, including infections that have reached the kidneys</p><p style="margin-left:-9.0pt; margin-right:-51.5pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->anthrax inhalation exposure</p><p style="margin-left:-40.5pt; margin-right:-51.5pt">It may also be used to treat other specific severe infections in children and adolescents when your doctor considered this necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:-9.0pt; margin-right:-47.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; <!--[endif]-->If you are allergic (hypersensitive) to ciprofloxacin or to other quinolone drugs, or any of the other ingredients of Ciproquin tablet, listed in section 6 below.</p><p style="margin-left:-9.0pt; margin-right:-47.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--> If you are taking tizanidine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:-45.0pt; margin-right:-56.0pt">Always take Ciproquin tablet exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Your doctor will explain to you exactly how much Ciproquin you will have to take as well as how often and for how long. This will depend on the type of infection you have and how bad it is.</p><p style="margin-left:-45.0pt; margin-right:-56.0pt">&nbsp;</p><p style="margin-left:-45.0pt; margin-right:-56.0pt">Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.</p><p style="margin-left:-45.0pt; margin-right:-56.0pt">The treatment usually lasts from 5 to 21 days, but may take longer for severe infections.</p><p style="margin-left:-45.0pt; margin-right:-56.0pt">&nbsp;</p><p style="margin-left:-45.0pt; margin-right:-56.0pt">&nbsp;Swallow the tablets with plenty of fluid. Do not chew the tablets because they do not taste nice, do try to take the tablets at around the same time every day, you can take the tablets at mealtimes or between meals. Any calcium you take as part of a meal will not seriously affect uptake.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:-45.0pt">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">Stop taking ciprofloxacin and see a doctor or go to a hospital immediately in order to consider another antibiotic treatment if you notice the following side effects:</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">&nbsp;</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">&nbsp;<strong>Rare</strong> (may affect up to 1 in 1,000 people):</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">Seizur</p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>Very rare</strong> (may affect up to 1 in 10,000 people):</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">Severe, sudden allergic reaction with symptoms such as tightness in the chest, feeling dizzy, sick or faint, or experience dizziness when standing up (anaphylactic reaction/shock), muscle weakness, inflammation of the tendons which could lead to rupture of the tendon, particularly affecting the large tendon at the back of the ankle, a serious life-threatening skin rash, usually in the form of blisters or ulcers in the mouth, throat, nose, eyes and other mucous membranes such as genitals which may progress to widespread blistering or peeling of the skin.</p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>Common</strong> (may affect up to 1 in 10 people):</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">Nausea, diarrhea, joint pain and joint inflammation in children.</p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>&nbsp;</strong></p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>Uncommon</strong> (may affect up to 1 in 100 people):</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">Joint pain in adults, fungal superinfections, a high concentration of eosinophils, a type of white blood cell, decreased appetite, hyperactivity or agitation, headache, dizziness, sleeping problems, or taste disorders, vomiting, abdominal pain, digestive problems such as (indigestion/heartburn), or wind, increased amounts of certain substances in the blood (transaminases and/or bilirubin), rash, itching, or hives, poor kidney function, pains in your muscles and bones, feeling unwell, or fever, increase in blood alkaline phosphatase (a certain substance in the blood).</p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>&nbsp;</strong></p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>Rare</strong> (may affect up to 1 in 1,000 people):</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">Muscle pain, inflammation of the joints, increased muscle tone and cramping, inflammation of the bowel linked to antibiotic use (can be fatal in very rare cases), changes to the blood count, increased or decreased amounts of a blood clotting factor, allergic reaction, swelling, or rapid swelling of the skin and mucous membranes, increased blood sugar, decreased blood sugar, confusion, disorientation, anxiety reactions, strange dreams, depression, or hallucinations, pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors, or giddiness, eyesight problems including double vision, tinnitus, loss of hearing, impaired hearing, rapid heartbeat, expansion of blood vessels, low blood pressure, or fainting, shortness of breath, including asthmatic symptoms, liver disorders, jaundice, or hepatitis, sensitivity to light, kidney failure, blood or crystals in the urine, urinary tract inflammation, fluid retention or excessive sweating, increased levels of the enzyme amylase.</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">&nbsp;</p><p style="margin-left:-45.0pt; margin-right:-51.5pt"><strong>Very rare</strong> (may affect up to 1 in 10,000 people):</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">A special type of reduced red blood cell count; a dangerous drop in a type of white blood cells; a drop in the number of red and white blood cells and platelets, which may be fatal; and bone marrow depression, which may also be fatal, allergic reaction called serum sickness-like reaction, mental disturbances, migraine, disturbed coordination, unsteady walk, disorder of sense of smell, pressure on the brain, visual colour distortions, inflammation of the wall of the blood vessels, pancreatitis, death of liver cells &nbsp;very rarely leading to life-threatening liver failure, small, pin-point bleeding under the skin; various skin eruptions or rashes, worsening of the symptoms of myasthenia gravis.</p><p style="margin-left:-45.0pt; margin-right:-51.5pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:-45.0pt; margin-right:-65.0pt">Keep out of the reach and sight of children.</p><p style="margin-left:-45.0pt; margin-right:-65.0pt">Store below 30<sup>◦</sup>C. Store in the original packaging</p><p style="margin-left:-45.0pt; margin-right:-65.0pt">Do not use Ciproquin tablet after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.</p><p style="margin-left:-45.0pt; margin-right:-65.0pt">Medicines should not be disposed of via waste water or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:-45.0pt">The active substance is ciprofloxacin</p><p style="margin-left:-45.0pt">The other ingredients are: starch, cellulose, crospovidone, silica, magnesium, ready mixed powder, and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ciproquin 250 mg tablets are oblong, white to off-white tablets engraved with “PRN250” and break line on one side and “HAYAT” on another side, available in packs of 10 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:-45pt; text-align:center">Hayat Pharmaceutical Industries Co. PLC</p><p style="margin-left:-45pt; text-align:center">P.O. Box 1564, Amman 11118 Jordan</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="margin-left:-63.0pt; margin-right:-.75in; text-align:right">قرص سيبروكوين يحتوي على مادة فعالة تسمى سيبروفلوكساسين. &nbsp;سيبروفلوكساسين هو مضاد حيوي ينتمي إلى عائلة الفلوروكينولون. وهو يعمل عن طريق قتل البكتيريا التي تسبب الإلتهاب. انه يعمل فقط مع سلالات معينة من البكتيريا.</p><p dir="RTL" style="margin-left:-63.35pt; margin-right:-.75in; text-align:right"><strong>&nbsp;وهو يستخدم في البالغين لعلاج</strong><strong>:</strong></p><p dir="RTL" style="margin-left:-63.35pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهابات الجهاز التنفسي،</p><p dir="RTL" style="margin-left:-63.35pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;و إصابات الأذن أو الجيوب الأنفية طويلة الأمد أو المتكررة،</p><p dir="RTL" style="margin-left:-63.35pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;والتهابات المسالك البولية،</p><p dir="RTL" style="margin-left:-63.35pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->والتهابات الجهاز التناسلي في الرجال والنساء،</p><p dir="RTL" style="margin-left:-63.35pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;والتهابات الجهاز الهضمي والالتهابات داخل البطن و</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;التهابات الجلد والأنسجة الرخوة،</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->والتهابات العظام والمفاصل،</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-.5in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;لمنع الالتهاب الناتج عن&nbsp; البكتيريا النيسرية السحائية، و عن التعرض لاستنشاق&nbsp; الجمرة الخبيثة.</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:3.0pt">&nbsp;</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->و يمكن استخدامه في علاج المرضى الذين يعانون من انخفاض عدد خلايا الدم البيضاء و الذين لديهم حمى يشتبه في أن تكون بسبب عدوى بكتيرية.</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;إذا كان لديك التهاب حاد أو التهاب ناتج&nbsp; عن&nbsp; أكثر من نوع واحد من البكتيريا، قد تعطى علاج بمضادات حيوية إضافية بالإضافة إلى سيبروفلوكساسين.</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وهو يستخدم في الأطفال والمراهقين تحت إشراف طبي متخصص لعلاج التهابات الرئة والشعب الهوائية لدى الأطفال والمراهقين الذين يعانون من التليف الكيسي، والتهابات المسالك البولية المعقدة، بما في ذلك الإلتهابات التي وصلت الى الكليتين، والتعرض لاستنشاق الجمرة الخبيثة. &nbsp;</p><p dir="RTL" style="margin-left:-63.0pt; margin-right:-45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ويمكن أيضا أن تستخدم لعلاج التهابات شديدة أخرى معينة&nbsp; في الأطفال والمراهقين عندما يعتبر الطبيب هذا ضروري.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in">إذا كانت لديك حساسية (فرط الحساسية) لسيبروفلوكساسين أو غيرها من الأدوية الكينولونية، أو أي من المكونات الأخرى من قرص سيبروكوين، المدرجة في القسم 6 أدناه.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in">&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in">&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in"><strong>تحذيرات واحتياطات عند استخدام قرص سيبروكوين</strong></p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.5pt; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك في أي وقت مضى مشاكل في الكلى لأن العلاج الخاص بك قد يحتاج إلى تعديل الجرعة،</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.5pt; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعاني من الصرع أو غيرها من الحالات العصبية،</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.5pt; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت قد عانيت من مشاكل الأوتار أثناء العلاج السابق بالمضادات الحيوية مثل سيبروفلوكساسين،</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.5pt; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مريض سكري لأنك قد تواجه خطر نقص سكر الدم مع سيبروفلوكساسين،</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.5pt; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;إذا كان لديك&nbsp; مشاكل في القلب. ينبغي توخي الحذر عند استخدام سيبروفلوكساسين، &nbsp;إذا كنت تعاني منذ الولادة أنت أو أحد أفراد عائلتك من تطاول للفترة QT (المرئية&nbsp; في تخطيط القلب، والتسجيل الكهربائي للقلب)، وعدم توازن الملح في الدم (وخاصة انخفاض مستوى البوتاسيوم أو المغنيسيوم في الدم )، إذا كان لديك إيقاع قلب بطيء جدا، أو لديك ضعف في القلب، أو لديك&nbsp; تاريخ من النوبات القلبية، أو إذا كنت أنثى أو من كبار السن أو كنت تأخذ أدوية أخرى تؤدي إلى تغييرات ECG غير طبيعية. إذا كنت أنت أو أحد أفراد عائلتك من المعروف أن لديه نقص في ديهيدروجيناز الجلوكوز 6 فوسفات، لأنك قد تواجه خطر الإصابة بفقر الدم مع سيبروفلوكساسين.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.5pt; text-align:justify; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;لعلاج بعض التهابات الجهاز التناسلي، يمكن للطبيب أن يصف المضادات الحيوية الأخرى بالإضافة إلى سيبروفلوكساسين. إذا لم يكن هناك تحسن في الأعراض بعد 3 أيام من العلاج، يرجى استشارة الطبيب.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-49.5pt; text-align:justify"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-58.5pt; margin-right:-49.5pt; text-align:justify">مؤخرا أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية. وذلك لأن هذه الأدوية قد تؤثر على طريقة عمل سيبروكوين. &nbsp;أيضا، سيبروكوين قد يؤثر على طريقة عمل هذه الأدوية.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.7pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>لا تأخذ سيبروكين جنبا إلى جنب مع تيزانيدين،</strong> لأن هذا قد يسبب آثار جانبية مثل انخفاض ضغط الدم والنعاس.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.7pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;<strong>من المعروف أن الأدوية التالية تتفاعل مع سيبروفلوكساسين في جسمك:</strong><br />مضادات فيتامين ك أو غيرها من مضادات التخثر الفموية، بروبينسيد، ميثوتريكسيت، ثيوفيلين، تيزانيدين، أولانزابين، كلوزابين، روبينيول، الفينيتوين، ميتوكلوبراميد، السيكلوسبورين، والأدوية الأخرى التي يمكن أن تغير إيقاع القلب، مضادات الاكتئاب ثلاثية الحلقات، بعض مضادات الميكروبات (التي تنتمي إلى مجموعة من الماكروليدات)، وبعض مضادات الذهان، الزولبيديم.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.7pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;سيبروفلوكساسين قد <strong>يزيد</strong> من مستويات الأدوية التالية في الدم: البنتوكسيفيلين، الكافيين، دولوكستين، ليدوكائين، سيلدينافيل، أغوميلاتين.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-13.7pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بعض الأدوية <strong>تقلل</strong> من تأثير سيبروكوين:</p><p dir="RTL" style="margin-left:-58.3pt; margin-right:-31.7pt; text-align:right">&nbsp;أخبر طبيبك إذا كنت تأخذ أو ترغب في أخذ: مضادات الحموضة، أوميبرازول، والمكملات المعدنية، ساكرالفات، بوليميريك فوسفات بايندر، والأدوية أو المكملات التي تحتوي على الكالسيوم والمغنيسيوم والألومنيوم أو الحديد. إذا كانت هذه التحضيرات ضرورية، تناول سيبروكوين قبل ساعتين أو قبلها بأربع ساعات.</p><p dir="RTL" style="margin-left:-58.3pt; margin-right:-13.7pt">&nbsp;</p><p dir="RTL" style="margin-left:-58.3pt; margin-right:-49.7pt; text-align:right"><strong>تناول قرص&nbsp; سيبروكوين مع الطعام أو الشراب</strong></p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-49.7pt; text-align:right">ما لم&nbsp; تتناول سيبروكوين خلال وجبات الطعام، لا تأكل أو تشرب أي من منتجات الألبان (مثل الحليب أو الزبادي) أو المشروبات المضاف إليها الكالسيوم عند تناول الأقراص، لأنها قد تؤثر على امتصاص المادة الفعالة.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">مثل جميع الأدوية، بمكن أن يسبب هذا الدواء تأثيرات غير مرغوبة، لكنها لا تحصل بالضرورة للجميع.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">توقف عن تناول سيبروفلوكساسين و راجع الطبيب أو إذهب إلى المستشفى على الفور من أجل اعتماد علاج مضاد حيوي آخر إذا لاحظت الآثار الجانبية التالية:</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;<strong>نادرة</strong> (قد تؤثر على ما يصل إلى 1 من 1000 شخص):</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">اختلاجات،</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify"><strong>نادرة جدا</strong> (قد تؤثر على ما يصل إلى 1 من 10،000 شخص):</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">رد فعل تحسسي حاد ومفاجئ مع أعراض مثل ضيق في الصدر، والشعور بالدوار، والمرضى أو الوهن، أو التعرض للدوخة عند الوقوف (رد فعل تحسسي/ صدمة)، وضعف العضلات، والتهاب الأوتار التي يمكن أن تؤدي إلى تمزق الوتر، مما يؤثر بشكل خاص على الوتر الكبير في الجزء الخلفي من الكاحل، و طفح جلدي خطير و مهدد للحياة ، يكون عادة على شكل بثور أو قرحة في الفم والحلق والأنف والعينين والأغشية المخاطية الأخرى مثل الأعضاء التناسلية التي قد تتطور إلى تفتت واسع النطاق أو تقشير الجلد.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify"><strong><u>الآثار الجانبية الأخرى التي لوحظت أثناء العلاج مع سيبروفلوكساسين وترد أدناه حسب مدى احتمال حدوثها</u></strong><strong>:</strong></p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;<strong>شائعة</strong> (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;الغثيان والإسهال وآلام المفاصل والتهاب المفاصل في الأطفال.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify"><strong>غير شائع</strong> (قد يؤثر على ما يصل إلى 1 من كل 100 شخص):</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">ألم المفاصل في البالغين، التهابات فطرية مضاعفة، تركيز عال من الإسينوفيلات،و هي نوع من خلايا الدم البيضاء، انخفاض الشهية، فرط النشاط أو التحريض، الصداع، الدوخة، مشاكل النوم، أو اضطرابات الطعم ، والقيء، وآلام في البطن، ومشاكل في الجهاز الهضمي مثل (عسر الهضم / حرقة) أو الغازات، وزيادة كميات من بعض المواد في الدم (الترانساميناز و / أو البيليروبين)، والطفح الجلدي، والحكة، أو خلايا النحل، وضعف وظائف الكلى، وآلام في العضلات والعظام، والشعور بالتوعك، أو الحمى، وزيادة في الفوسفاتيز القلوية في الدم (مادة معينة في الدم).</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;<strong>نادرة (</strong>قد يؤثر على ما يصل إلى 1من كل 1000 شخص):</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;آلام في العضلات، التهاب المفاصل، زيادة شد و تشنجات العضلات، التهاب الأمعاء المرتبط باستخدام المضادات الحيوية (يمكن أن تكون قاتلة في حالات نادرة جدا)، تغييرات في حسابات مكونات الدم، زيادة أو نقصان كميات عامل تخثر الدم، أو رد فعل تحسسي، تورم، أو تورم سريع في الجلد والأغشية المخاطية، وزيادة نسبة السكر في الدم، وانخفاض نسبة السكر في الدم، والارتباك، و عدم القدرة على التوجه،&nbsp; وردود الفعل القلق، أحلام غريبة، والاكتئاب، أو الهلوسة، حساسية غير عادية لمحفزات الحواس مثل الإبر والدبابيس، وانخفاض حساسية الجلد، والهزات، أو الجرأة، ومشاكل البصر بما في ذلك ضعف الرؤية، وطنين، وفقدان السمع، وضعف السمع، وسرعة ضربات القلب، وتوسيع الأوعية الدموية، وانخفاض ضغط الدم، أو الإغماء، وضيق التنفس، بما في ذلك أعراض الربو، واضطرابات الكبد، واليرقان، أو التهاب الكبد، والحساسية للضوء والفشل الكلوي وظهور الدم أو الحصى في البول والتهاب المسالك البولية واحتباس السوائل أو التعرق المفرط، وزيادة مستويات انزيم الأميليز.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify"><strong>نادرة جدا</strong>(قد تؤثر على ما يصل إلى 1 من كل 10،000 شخص): ن</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">وع خاص من انخفاض عدد خلايا الدم الحمراء. انخفاض خطير في نوع من خلايا الدم البيضاء. انخفاض في عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية، والتي قد تكون قاتلة. ونقص نخاع العظام، والذي قد يكون أيضا قاتلا، رد فعل تحسسي يسمى المصل رد فعل مثل المرض، واضطرابات نفسية، والصداع النصفي، والتنسيق المضطرب، والمشي الغير مستقر، واضطراب في الشعور بالرائحة، والضغط على الدماغ، وتشوهات اللون البصري، والتهاب جدار الأوعية الدموية، والتهاب البنكرياس، وفقدان خلايا الكبد و الذي نادرا ما يؤدي إلى فشل الكبد المهدد للحياة، نقط نزيف صغيرة كالدبوس تحت الجلد. الانفجارات الجلدية المختلفة أو الطفح الجلدي، وتفاقم أعراض الوهن العضلي الوبيل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">يحفظ بعيدا عن متناول ايدي الاطفال وعن مجال بصرهم.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">يحفظ في حرارة اقل من 30 درجة مئوية، ضمن عبوته الاصلية .</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">لا تستعمل قرص سيبروكوين بعد تاريخ انتهاء الصلاحية المدون على العلبة وعلى الشريط. تاريخ انتهاء الصلاحية يعني اليوم الاخير من ذلك الشهر.</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">&nbsp;يجب عدم رمي الادوية بتاتا في المجاري أو النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الادوية التي لم تعد بحاجة لها. هذه التدابير تسمح بحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:justify">المادة الفعالة هي سيبروفلوكساسين</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-.75in; text-align:right">المكونات الأخرى: نشا الذرة، السليلوز الجريزوفولفين، كروسبوفيدون، السيليكا الغروية، ستيرات المغنيسيوم، بودرة بيضاء مخلوطة جاهزة &nbsp;مكونة من (هايبرو سيللوز، ثنائي أكسيد التيتانيوم، بولي اثيلين جلايكول،لاكتوز)، وماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:left">C</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-58.5pt; margin-right:-0.75in; text-align:center">شركة الحياة للصناعات الدوائية م.ع.م&nbsp;</p><p dir="RTL" style="margin-left:-58.5pt; margin-right:-0.75in; text-align:center">ص.ب 1564عمان 11118 الأردن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أيار 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ciproquin 500 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Ciproquin500 mg contains 600 mg ciprofloxacin HCL monohydrate, equivalent to
500 mg ciprofloxacin.Excipient(s) with known effect:This medicine contains Lactose, so patients with rare hereditary problems of g a lactose
intolerance, the Lapp lactase deficiency or glucose-g a lactose malabsorption should not takethis medicine.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TabletCiproquin 250 mg tablets: Oblong, white tooff-whitetablets engraved with“PRN250” and break
line on one side and “HAYAT” on anotherside.Ciproquin 500 mg tablets: Oblong, white to off-white tablets engraved with “PRN500” and breakline on one side and “HAYAT” on another side.
The tablet can be divided into equal halves.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ciproquin is indicated for the treatmentofthe following infections (see sections 4.4 and5.1).<br />Special attention should be paid to available information on resistance to ciprofloxacin beforecommencing therapy.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.Adults:<br /> Lower respiratory tract infections due to Gram-negative bacteria- exacerbations of chronic obstructive pulmonary disease- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis- pneumonia<br /> Chronic suppurative otitis media Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative<br />bacteria Urinary tract infections Genital tract infections<br />- gonococcal uretritis and cervicitis due to susceptibleNeisseria gonorrhoeae- epididymo-orchitis including cases due to susceptibleNeisseria gonorrhoeae- pelvic inflammatory disease including cases due to susceptibleNeisseria<br />gonorrhoeae Infections of the gastro-intestinal tract(e.g. travellers&#39; diarrhoea) Intra-abdominal infections Infections of the skin and soft tissue caused by Gram-negative bacteria Malignant external otitis Infections of the bones and joints Prophylaxis of invasive infections due toNeisseriameningitides Inhalation anthrax (post-exposure prophylaxis and curative treatment)<br />Ciprofloxacin may be used in the management of neutropenic patients with fever that issuspected to be due to abacterial infection.<br />Children and adolescents Broncho-pulmonary infections in cystic fibrosis caused byPseudomonas aeruginosa Complicated urinary tract infections and pyelonephritis Inhalation anthrax (post-exposure prophylaxis and curative treatment)<br />Ciprofloxacin may also be used to treat severe infections in children and adolescents whenthis is considered to be necessary.Treatment should be initiated only by physicians who are experienced in the treatment ofcystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PosologyThe dosage is determined by the indication, the severity and the site of the infection, the<br />susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, inchildren and adolescentsthe body weight.<br />The duration of treatment depends on the severity of the illness and on the clinical andbacteriological course.<br />Treatment of infections due to certain bacteria (e.g.Pseudomonas aeruginosa,AcinetobacterorStaphylococci)may require higher ciprofloxacin doses and co-administration with other appropriateantibacterial agents.<br />Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infectionsin neutropenicpatients and infections of bones and joints) mayrequire co-administration with otherappropriate antibacterial agentsdepending on the pathogens involved.</p><p>Method of administration:Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If<br />taken on an empty stomach, the active substance is absorbed more rapidly.Ciprofloxacin tabletsshould not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g.calcium-fortified orange juice) (see section 4.5).<br />In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it isrecommended to commence therapy with intravenous ciprofloxacin until a switch to oraladministration is possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1.
Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Severe infections and mixed infections with Gram-positive and anaerobic pathogensCiprofloxacin monotherapy is not suitedfor treatment of severe infections and infections that mightbe due toGram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriateantibacterial agents.Streptococcal Infections (including Streptococcus pneumoniae)Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequateefficacy.Genital tract infectionsGonococcal uretritis, cervicitis, epididymo-orchitis and pelvic inflammatory diseases may be causedby fluoroquinolone-resistant Neisseria gonorrhoeae isolates.Therefore, ciprofloxacin should be administered for the treatment of gonococcal uretritis or cervicitisonly if ciprofloxacin-resistantNeisseria gonorrhoeaecan be excluded.For epididymo-orchitis andpelvic inflammatory diseases, empirical ciprofloxacin should only beconsidered incombination with another appropriate antibacterial agent (e.g. a cephalosporin) unlessciprofloxacin-resistantNeisseriagonorrhoeaecan be excluded. If clinical improvement is notachieved after 3 days of treatment, the therapy should bereconsidered.Urinary tract infectionsResistance to fluoroquinolones of Escherichia coli &ndash;the most common pathogen involved in urinarytract infections&ndash;varies across the European Union. Prescribers are advised to take into account the<br />local prevalence of resistance inEscherichia coli to fluoroquinolones.<br />The single dose of ciprofloxacin that may be used in uncomplicated cystitis in pre-menopausalwomen is expected tobe associated with lower efficacy than the longer treatment duration. This is allthe more to be taken into account asregards the increasing resistance level of Escherichia coli toquinolones.Intra-abdominal infectionsThere are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.<br />Travellers&#39;diarrheaThe choice of ciprofloxacin should take into account information on resistance to ciprofloxacin inrelevant pathogens inthe countries visited.<br />Infections of the bones and jointsCiprofloxacin should be used in combination with other antimicrobial agents depending on the resultsof themicrobiological documentation.<br />Inhalational anthraxUse in humans is based on in-vitrosusceptibility data and on animal experimental datatogether withlimited humandata. Treating physicians should refer to national and/or international consensusdocuments regarding the treatment of anthrax.<br />Paediatric populationThe use of ciprofloxacin in children and adolescents should follow availableofficial guidance.Ciprofloxacin treatmentshould be initiated only by physicians who are experienced in the treatmentof cystic fibrosis and/or severe infections inchildren and adolescents.<br />Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals.Safety data from arandomised double-blind study on ciprofloxacin use in children (ciprofloxacin:n=335, mean age = 6.3 years;comparators: n=349, mean age = 6.2 years; age range = 1 to 17years) revealed an incidence of suspecteddrug-related arthropathy (discerned from joint-relatedclinical signs and symptoms) by Day +42 of 7.2% and 4.6%.Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-relatedarthropathy cases over time was not statistically significant between groups. Treatment shouldbeinitiated only after a careful benefit/risk evaluation, due to possible adverse events related to jointsand/orsurrounding tissue (see section 4.8).<br />Broncho-pulmonary infections in cystic fibrosisClinical trials have included children and adolescents aged 5-17 years. More limited experience isavailable in treatingchildren between 1 and 5 years of age.<br />Complicated urinary tract infections and pyelonephritisCiprofloxacin treatment of urinary tract infections should be considered when other treatments cannotbe used, andshould be based on the results of the microbiological documentation.Clinical trials have included children and adolescents aged 1-17 years.<br />Other specific severe infectionsOther severe infections in accordance with official guidance, or after careful benefit-risk evaluationwhen othertreatments cannot be used, or after failure to conventional therapy and when themicrobiological documentation can justify a ciprofloxacin use.The use of ciprofloxacin for specific severe infections other than those mentioned above has notbeen evaluated inclinical trials and the clinical experience is limited. Consequently, caution isadvised when treating patients with these infections.<br />HypersensitivityHypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occurfollowing a singledose (see section 4.8) and may be life-threatening. If such reaction occurs,ciprofloxacin should be discontinued and anadequate medical treatment is required.<br />Musculoskeletal System<br />Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorderrelated to quinolonetreatment. Nevertheless, in very rare instances, after microbiologicaldocumentation of the causative organism andevaluation of the risk/benefit balance, ciprofloxacinmay be prescribed to these patients for the treatment of certainsevere infections, particularly in theevent of failure of the standard therapy or bacterial resistance, where themicrobiological data mayjustify the use of ciprofloxacin.Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur withciprofloxacin, even within the first 48 hoursof treatment. Inflammation and ruptures of tendon mayoccur even up to several months afterdiscontinuation of ciprofloxacin therapy. The risk oftendinopathy may be increased in elderly patients or in patientsconcomitantly treated withcorticosteroids (see section 4.8).At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should bediscontinued. Careshould be taken to keep the affected limb at rest.Ciprofloxacin should be used with caution in patients with myastheniagravis, because symptoms canbeexacerbated (see section 4.8).<br />Vision disordersIf vision becomes impaired or any effects on the eyes are experienced, an eye specialist should beconsulted immediately.<br />PhotosensitivityCiprofloxacin has been shown tocause photosensitivity reactions. Patients taking ciprofloxacinshould be advised toavoid direct exposure to either extensive sunlight or UV irradiation duringtreatment (see section 4.8).<br />Central Nervous SystemCiprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold.Cases of statusepilepticus have been reported. Ciprofloxacin should be used with caution in patientswith CNS disorders which may bepredisposed to seizure. If seizures occur ciprofloxacin should bediscontinued (see section 4.8). Psychiatric reactionsmay occur even after first administration ofciprofloxacin. In rare cases, depression or psychosis can progress tosuicidal ideations/thoughtsculminating in attempted suicide or completed suicide. In the occurrence of such cases,ciprofloxacinshould be discontinued.Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensorydisturbances or muscleweakness, alone or in combination) have been reported in patients receivingciprofloxacin. Ciprofloxacin should bediscontinued in patients experiencing symptoms of neuropathy,including pain, burning, tingling, numbness, and/orweakness in order to prevent the development ofan irreversible condition (see section 4.8).<br />Cardiac disordersCaution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with knownrisk factors forprolongation of the QT interval such as, for example:<br /> Congenital long QT syndrome Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-<br />arrhythmics, tricyclicantidepressants, macrolides, antipsychotics) Uncorrectedelectrolyte imbalance (e.g.hypokalaemia, hypomagnesaemia) Cardiacdisease (e.g. heart failure, myocardial infarction, bradycardia)<br />Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore,caution should be takenwhen using fluoroquinolones, including ciprofloxacin, in thesepopulations. (See section 4.2 Elderly patients, section 4.5, section 4.8,andsection4.9).<br />HypoglycemiaAs with other quinolones, hypoglycemia has been reported most often in diabetic patients,predominantly in the elderlypopulation. In all diabetic patients, careful monitoring of blood glucose isrecommended (see section 4.8).<br />Gastrointestinal SystemThe occurrence of severe and persistent diarrhoea during or after treatment (including several weeks<br />after treatment)may indicate an antibiotic-associated colitis (life-threatening with possible fatal<br />outcome), requiring immediatetreatment (see section 4.8). In such cases, ciprofloxacin shouldimmediately be discontinued, and an appropriatetherapy initiated. Anti-peristaltic drugs arecontraindicated in this situation.<br />Renal and urinary systemCrystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receivingciprofloxacinshould be well hydrated and excessive alkalinity of the urine should be avoided.<br />Impaired renal functionSince ciprofloxacin is largely excreted unchanged via renal pathwaydose adjustment is needed inpatients with impaired renal function as described in section 4.2 to avoid an increase in adverse drugreactions due to accumulationof ciprofloxacin.<br />Hepatobiliary systemCases of hepatic necrosis and life-threateninghepatic failure have been reported with ciprofloxacin(see section 4.8). Inthe event of any signs and symptoms of hepatic disease (such as anorexia,jaundice, dark urine, pruritus, or tenderabdomen), treatment should be discontinued.<br />Glucose-6-phosphatedehydrogenase deficiencyHaemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphatedehydrogenasedeficiency. Ciprofloxacin should be avoided in these patients unless the potentialbenefit is considered to outweigh thepossible risk. In this case, potential occurrence of haemolysisshould be monitored.<br />ResistanceDuring or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance tociprofloxacin maybe isolated, with or without a clinically apparent superinfection. There may be aparticular risk of selecting forciprofloxacin-resistant bacteria during extended durations of treatmentand when treating nosocomial infections and/or infections caused byStaphylococcusandPseudomonasspecies.<br />Cytochrome P450Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantlyadministeredsubstances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine,ropinirole, tizanidine, duloxetine,agomelatine).Therefore, patients taking these substancesconcomitantly with ciprofloxacin should be monitored closelyfor clinical signs of overdose, anddetermination of serum concentrations (e.g. of theophylline) may be necessary (seesection 4.5). Co-administrationof ciprofloxacin and tizanidine is contra-indicated.<br />MethotrexateThe concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).<br />Interaction with testsThe in-vitroactivity of ciprofloxacin againstMycobacteriumtuberculosismight give false negativebacteriological testresults in specimens from patients currently taking ciprofloxacin.<br />This medicine contains lactose, so patients with rarehereditary problems of galactose intolerance,the Lapp lactasedeficiency or glucose-galactosemalabsorption should not takethis medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other products on ciprofloxacinDrugs known to prolong QT intervalCiprofloxacin, likeother fluoroquinolones, should be used with caution in patients receiving drugs<br />known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants,macrolides, antipsychotics) (see section 4.4).<br />Chelation Complex Formation<br />Thesimultaneous administration of ciprofloxacin (oral) and multivalent cation-containing drugs andmineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g.sevelamer or lanthanum carbonate), sucralfate or antacids, andhighly buffered drugs (e.g.didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption ofciprofloxacin. Consequently, ciprofloxacin should be administered either 1-2 hours before or at least4 hours after these preparations. The restriction does not apply to antacids belonging to the class ofH2 receptor blockers.<br />Food and Dairy ProductsDietary calcium as part of a meal does not significantly affect absorption. However, the concurrent<br />administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortifiedorange juice) with ciprofloxacinshould be avoided because absorption of ciprofloxacin may bereduced.<br />ProbenecidProbenecid interferes with renal secretion of ciprofloxacin. Co-administrationof probenecid and<br />ciprofloxacin increasesciprofloxacin serum concentrations.MetoclopramideMetoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach<br />maximum plasmaconcentrations. No effect was seen on thebioavailability of ciprofloxacin.OmeprazoleConcomitant administration of ciprofloxacin and omeprazole containing medicinal products results in<br />a slight reduction of C<br />and AUC of ciprofloxacin.Effects of ciprofloxacin on other medicinal productsTizanidineTizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study<br />max<br />with healthysubjects, there was an increase in serum tizanidine concentration (C<br />increase: 7-fold,range: 4 to 21-fold; AUC increase: 10-fold,range: 6 to 24-fold) when given concomitantly withciprofloxacin. Increased serum tizanidineconcentration is associated with a potentiated hypotensiveand sedative effect.<br />MethotrexateRenal tubular transport of methotrexate may be inhibited by concomitant administration of<br />ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk ofmethotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).<br />TheophyllineConcurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in<br />serum theophylline concentration. This can lead to theophylline-induced side effects that may rarelybe life threatening or fatal. During the combination, serum theophylline concentrations should bechecked and the theophylline dose reduced as necessary (see section 4.4).<br />Other xanthine derivativesOn concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised<br />max<br />serum concentrations of these xanthine derivatives were reported.PhenytoinSimultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum<br />levels of phenytoin such that monitoring of drug levels is recommended.CyclosporinA transient rise in the concentration of serum creatinine was observed when ciprofloxacin and<br />cyclosporin containingmedicinal products were administered simultaneously. Therefore, it isfrequently (twice a week) necessary to control the serum creatinine concentrations in these patients.<br />Vitamin K antagonists<br />Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. Therisk may vary with the underlying infection, age and general status of thepatient so that the contribution of ciprofloxacinto the increase in INR (international normalised ratio)is difficult to assess. The INR should be monitored frequentlyduring and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol,phenprocoumon, or fluindione).<br />DuloxetineIn clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the<br />CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and Cmaxofduloxetine. Although no clinical data areavailable on a possible interaction with ciprofloxacin, similareffects can be expected upon concomitant administration(see section 4.4). RopiniroleIt was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate<br />inhibitor of the CYP4501A2 isozyme, results in an increase of C<br />and AUC of ropinirole by 60%and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment asappropriate is recommended during and shortly after co-administration with ciprofloxacin (see section4.4).<br />max<br />LidocaineIt was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal<br />products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance ofintravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interactionwith ciprofloxacin associated with side effects may occur upon concomitant administration.<br />ClozapineFollowing concomitantadministration of 250 mg ciprofloxacin with clozapine for 7 days, serum<br />concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%,respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortlyafter co-administration with ciprofloxacin are advised (see section 4.4).<br />SildenafilC<br />and AUC of sildenafil were increased approximately two fold in healthy subjects after an oraldose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be usedprescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and thebenefits.<br />max<br />AgomelatineIn clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2<br />isoenzyme,markedly inhibits the metabolism of agomelatine resulting in a 60-fold increase ofagomelatine exposure. Although no clinical data are available for a possible interaction withciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitantadministration (see &#39;Cytochrome P450&#39; in section 4.4).<br />ZolpidemCo-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not<br />recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PregnancyThe data that are available on administration of ciprofloxacin to pregnant women indicates nomalformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirectharmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed toquinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that thedrug could cause damage to articular cartilage in the human immature organism / foetus (see section5.3).As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.<br />Breast-feeding<br />Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacinshould not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to<br />operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) arenausea and diarrhoea.<br />ADRs derived from clinical studies and post-marketing surveillance withciprofloxacin (oral,intravenous, and sequential therapy) sorted by categories of frequency are listed below. Thefrequency analysis takes into account data frombothoral and intravenous administration ofciprofloxacin.</p><p>Paediatric populationThe incidence of arthropathy(arthralgia, arthritis), mentioned above, is referring to data collected in<br />studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g<br />has beenreported to cause acute renal failure.Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations,<br />confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria.Reversible renal toxicity has beenreported.<br />Apart fromroutine emergency measures, e.g. ventricular emptying followed by medical carbon, it isrecommended tomonitor renal function, including urinary pH and acidify, if required, to preventcrystalluria. Patients should be kept well hydrated. Calcium or magnesium containing antacids maytheoretically reduce the absorption of ciprofloxacin inoverdoses<br />Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis. Inthe event of overdose, symptomatic treatment should be implemented. ECG monitoring should beundertaken,because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:Fluoroquinolones, ATC code:J01MA02.Mechanism of actionAs a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the<br />inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNAreplication, transcription, repair and recombination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets,ciprofloxacin isabsorbed rapidly and extensively, mainly from the small intestine, reaching maximumserumconcentrations 1-2 hours later.<br />Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (C<br />)between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.The absolute bioavailability is approximately 70-80%.A 500 mg oral dose given every 12 hours hasbeen shown to produce an area under the serum concentration-time curve (AUC) equivalent to thatproduced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every12 hours.<br />DistributionProtein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-<br />ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacinreaches high concentrations in avariety oftissues such as lung (epithelial fluid, alveolar macrophages,biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine,prostate, endometrium) where total concentrations exceedingthose of plasmaconcentrations arereached.<br />BiotransformationLow concentrations of four metabolites have been reported, which were identified as:<br />desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) andformylciprofloxacin (M 4). The metabolites display in-vitroantimicrobial activity but to a lower degreethan the parent compound.<br />Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.EliminationCiprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum<br />eliminationhalf-life in subjects with normal renal function is approximately 4-7 hours.Excretion of ciprofloxacin (% of dose)<br />Oral AdministrationUrine Faeces<br />Ciprofloxacin 44.7 25.0Metabolites (M1-M4) 11.3 7.5<br />Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impairedrenal function leads to increasedhalf-livesof ciprofloxacin of up to 12 h.<br />Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism.1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in highconcentrations.<br />Paediatric patientsThe pharmacokinetic data in paediatric patients are limited. In a study in children C<br />and AUC werenot age-dependent (above one year of age). No notable increase in C<br />andAUC upon multipledosing (10 mg/kg three times daily) was observed.<br />In 10 children with severe sepsisC<br />max<br />max<br />was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenousinfusion of 10mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) forchildren between 1 and 5years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L)and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.<br />These values are within the range reported for adults at therapeutic doses. Based on populationpharmacokineticanalysis of paediatric patientswith various infections, the predicted mean half-life inchildren is approx. 4-5 hours andthe bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure<br />levels. Data on photomutagenicity/ photocarcinogenicity show a weak photomutagenic orphototumorigenic effect of ciprofloxacinin-vitro and in animal experiments. This effect was comparableto that of other gyrase inhibitors.<br />Articular tolerabilityAs reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints<br />in immature animals. The extent of the cartilage damage varies according to age, species and dose;the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog)revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin causedsevere articular changes at therapeutic doses after two weeks of treatment, which were still observedafter 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize starch</p><p>Microcrystallinecellulose</p><p>Crospovidone</p><p>Colloidal anhydrous silica</p><p>Magnesiumstearate</p><p>Ready mixed powder composed of (HPMC and TIO2 and PEG and Lactose)</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30◦C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aluminum blisters containing tablets.</p><p>Pack size for 250 mg tablets: 10 as commerciallyavailable.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;disposal and other handling</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hayat Pharmaceutical Industries Co. PLC
P. O. Box 1564 Amman 11118 Jordan
Tel. +962 6 416 2607
Fax.0096264163016
E-mail: hpi@nol.com.jo
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>